Fierce Biotech’s 2025 Fierce 15
Thermal Clients Formation Bio and Georgiamune Named to Fierce Biotech’s 2025 Fierce 15
Thermal is proud to announce that clients Formation Bio and Georgiamune have been recognized as two of Fierce Biotech’s 2025 Fierce 15 biotechnology companies—the industry’s most prestigious honor for early-stage innovation.
Formation Bio, led by CEO Benjamine Liu, is transforming drug development by using AI to clear clinical trial bottlenecks and make studies more affordable. The company is building what it calls “this generation’s enduring pharma company”—using automation and generative AI to accelerate the delivery of new medicines at a fraction of traditional cost and time.
Georgiamune, founded by immunotherapy pioneer Dr. Samir Khleif, is tackling one of medicine’s most pressing challenges by targeting T cell “master switches” to reprogram immune behavior. The company’s approach addresses core immune dysfunctions to make immunotherapies more effective for both cancer patients and those with autoimmune diseases.
Now in its 23rd year, the Fierce 15 spotlights private biotechs “pushing science into uncharted territory” with approaches that represent “genuine leaps forward.” This year’s class is defined by resilience, strategic diversity, and treatments with life-changing potential for underserved patients.
The recognition underscores both companies’ bold science and their commitment to solving critical unmet medical needs during one of biotech’s most challenging periods.
